Propanidid

Summary

Propanidid (CHEMBL2105345) is an approved small molecule (ATC N01AX04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01AX04
• Chemistry: 337.4 Da · C18H27NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105345
Name	Propanidid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	15004
ATC	N01AX04
Molecular formula	C18H27NO5
Molecular weight	337.4
InChIKey	KEJXLQUPYHWCNM-UHFFFAOYSA-N

SMILES: CCCOC(=O)CC1=CC(=C(C=C1)OCC(=O)N(CC)CC)OC

IUPAC name: propyl 2-[4-[2-(diethylamino)-2-oxoethoxy]-3-methoxyphenyl]acetate

Also known as: BAYER 1420, BAYER-1420, Epontol, FBA 1420, FBA-1420, Propanidid, Propanidide, TH-2180, WH 5668, WH-5668, PROPANIDID, SID144206858

Patent coverage: 322 distinct patent families (1,203 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).